Abdullah Sultan

Abdullah Sultan

Auto-generated profile, based on publicly available information

Abdullah Sultan

Neurodegenerative Disease Center, Scintillon Institute, San Diego, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2008 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKShahper N. Khan
Shahper N. Khan
BIBarira Islam
Barira Islam
RYRagothaman Yennamalli
Ragothaman Yennamalli
ASAbdullah Sultan
Abdullah Sultan
NSNaidu Subbarao
Naidu Subbarao
Asad KhanAsad Khan
Asad Khan

1 November 2017 in Cell Reports
Verified
Journal Article
Open access
COChang-Ki Oh
Chang-Ki Oh
ASAbdullah Sultan
Abdullah Sultan
JPJoseph Platzer
Joseph Platzer
NDNima Dolatabadi
Nima Dolatabadi
FSFrank Soldner
Frank Soldner
Stuart LiptonStuart Lipton
Stuart Lipton
Mutations in PARK6 (PINK1) and PARK2 (Parkin) are linked to rare familial cases of Parkinson's disease (PD). Mutations in these genes result in pathological dysregulation of mitophagy, contributing to neurodegeneration. Here, we report that environmental factors causing a specific posttranslational modification on PINK1 can mimic these genetic mutations. We describe a molecular mechanism for impairment of mitophagy via formation of S-nitrosylated PINK1 (SNO-PINK1). Mitochondrial insults simulating age- or environmental-related stress lead to increased SNO-PINK1, inhibiting its kinase activity. SNO-PINK1 decreases Parkin translocation to mitochondrial membranes, disrupting mitophagy in cell lines and human-iPSC-derived neurons. We find levels of SNO-PINK1 in brains of α-synuclein transgenic PD mice similar to those in cell-based models, indicating the pathophysiological relevance of our findings. Importantly, SNO-PINK1-mediated deficits in mitophagy contribute to neuronal cell death. These results reveal a direct molecular link between nitrosative stress, SNO-PINK1 formation, and mitophagic dysfunction that contributes to the pathogenesis of PD.

1 August 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
LLLi Li
Li Li
ETE Tian
E Tian
XCXianwei Chen
Xianwei Chen
JCJianfei Chao
Jianfei Chao
JKJeremy Klein
Jeremy Klein
YSYanhong Shi
Yanhong Shi

8 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
DTDorit Trudler
Dorit Trudler
KNKristopher L. Nazor
Kristopher L. Nazor
YEYvonne S. Eisele
Yvonne S. Eisele
TGTitas Grabauskas
Titas Grabauskas
NDNima Dolatabadi
Nima Dolatabadi
Stuart LiptonStuart Lipton
Stuart Lipton
Significance: Release of oligomeric/fibrillar α-synuclein (αSyn) from damaged neurons contributes to neuronal cell death in Parkinson’s disease and other neurodegenerative disorders in part via microglial activation. Here, we show that αSyn activates the NLRP3 inflammasome in human induced pluripotent stem cell (hiPSC)-derived microglia (hiMG) via dual stimulation involving TLR2 engagement and mitochondrial damage. Oligomerized amyloid-β peptide (Aβ), as found in Alzheimer’s disease brains, exacerbates this neuroinflammation. Importantly, we found that misfolded proteins such as αSyn and Aβ, when bound to antibody and presented to hiMG, result in enhanced proinflammatory response of the NLRP3 inflammasome. These findings may have important implications for antibody therapies aimed at depleting misfolded/aggregated proteins from the human brain, as they may paradoxically trigger neuroinflammation in human microglia.

14 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
STShichun Tu
Shichun Tu
MAMohd Waseem Akhtar
Mohd Waseem Akhtar
RERosa Maria Escorihuela
Rosa Maria Escorihuela
AAAlejandro Amador-Arjona
Alejandro Amador-Arjona
VSVivek Swarup
Vivek Swarup
NNNobuki Nakanishi
Nobuki Nakanishi
Transcription factor MEF2C regulates multiple genes linked to autism spectrum disorder (ASD), and human MEF2C haploinsufficiency results in ASD, intellectual disability, and epilepsy. However, molecular mechanisms underlyingMEF2Chaploinsufficiency syndrome remain poorly understood. Here we report thatMef2c+/−(Mef2c-het) mice exhibit behavioral deficits resembling those of human patients. Gene expression analyses on brains from these mice show changes in genes associated with neurogenesis, synapse formation, and neuronal cell death. Accordingly,Mef2c-het mice exhibit decreased neurogenesis, enhanced neuronal apoptosis, and an increased ratio of excitatory to inhibitory (E/I) neurotransmission. Importantly, neurobehavioral deficits, E/I imbalance, and histological damage are all ameliorated by treatment with NitroSynapsin, a new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/fast off-rate antagonist of NMDA-type glutamate receptors. These results suggest thatMEF2Chaploinsufficiency leads to abnormal brain development, E/I imbalance, and neurobehavioral dysfunction, which may be mitigated by pharmacological intervention.

29 May 2020 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
SGSwagata Ghatak
Swagata Ghatak
NDNima Dolatabadi
Nima Dolatabadi
RGRichard Gao
Richard Gao
YWYin Wu
Yin Wu
HSHenry Scott
Henry Scott
Stuart LiptonStuart Lipton
Stuart Lipton